Understanding Patient Centricity, Progress Made, and Barriers Encountered: A Survey of Industry Professionals

Laura L. Perry¹, Clarinda Cerejo⁷, Kwisha Shah⁷, Prerna Motwani⁷

¹Cactus Life Sciences, Cactus Communications, Princeton, NJ, USA; ²Cactus Life Sciences, Cactus Communications, Mumbai, India

INTRODUCTION

• Despite patient centricity being a point of discussion in pharma for years, patients have not been very satisfied with pharma’s patient centricity efforts.¹
• The industry does not have a common definition of patient centricity, and the parameters that help deliver patient value are still not clear.
• One solution to this is hyper-customization of pharma-generated content, e.g., patients can be shown how a treatment option fits into their individual lifestyle and needs.²

In this survey-based study, we aimed to gather opinions from industry professionals on what patient centricity means to them and their organization.

METHOD

• Cactus Communications commissioned a survey of industry professionals. The pharma journal PM360 conducted this study in collaboration with Litchfield Research, an independent research firm based in Rowell, GA.
• The survey was distributed via emails to PM360 and Cactus Life Sciences subscribers, and online via newsletters and social media.
• Responses were collected from January 4 to February 25, 2022.

RESULTS

We collected responses from a total of 31 pharma/biotech and associated industry professionals, who described medical affairs, clinical trials, and commercialization as their main areas of focus. Below are their responses to survey questions, ranked from most to least selected (percent responses).

### Definitions of Patient Centricity

- Patient’s well-being at the core of all initiatives
- Shift from disease-centered to a patient-centered strategy and from product-led to a patient-led development process
- Patient inclusion in the scientific process and in study development
- Health equity, inclusion, and drug access at all socio-economic levels
- Pharma’s internal structure adapted to prioritize patient-first initiatives
- Determining which patients to engage with (representativeness)
- Concerns about regulations governing engagement with patients
- Lack of trust from patients
- Historical precedent to only ask for clinicians’ input
- Lack of standard operating procedures relating to involving patients/caregivers
- Post-launch patient education
- Disease-state education initiatives
- Communication activities involving patients
- What patient centricity means to them and their organization
- The current state of patient involvement in drug development and clinical research publication
- The barriers to greater patient involvement

CONCLUSION

• Patient communities have adopted the phrase “nothing about us, without us” in their quest to be included as equal stakeholders in the healthcare system.³
• Our survey results indicate that while patient centricity has been gaining momentum as a strategic priority for biopharma, the industry is far from embodying this maxim with regard to patient involvement.
• Standardization of patient and caregiver involvement in drug development, medical communication initiatives, and clinical publications would augment the value currently being created by fragmented patient-centric activities.
• Medical affairs professionals can lead this standardization as they are the natural bridge of communication between the R&D and commercial segments.

LIMITATIONS

The small sample size of this survey prevents an in-depth and accurate understanding of the broader industry’s experience of and attitudes to patient centricity. Nevertheless, this study suffices as a starting point for a conversation toward stronger and more unified patient-centricity efforts.

Acknowledgments

• Moisten Benick, Medical Affairs—South Holland, The Netherlands
• Leah M. Beerman, Associate of Community Cancer Center—Kovalev MD, USA
• Lili Chu, International Association for Chronic Fatigue Syndrome/Myalgia Enervansatiæs
• Laura L. Perry, Clarinda Cerejo, Kwisha Shah, Prerna Motwani, Cactus Life Sciences, Cactus Communications, Princeton, NJ, USA

References


Rewritten by a former employee of Cactus Life Sciences, Cactus Communications, Mumbai, India. She is now associated with Cipla Ltd., Mumbai, India.